gene001web – Page 2 – GeneTether, Inc.

August 25, 2022

GeneTether Therapeutics Inc. Announces Second Quarter 2022 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – August 24, 2022

0

GeneTether Therapeutics Announces Issuance of New US Composition of Matter Patent for its Innovative Platform Technology Focused on Gene Editing Efficiency

San Lorenzo, California and Vancouver, British Columbia – May 25, 2022

0

GeneTether Therapeutics Inc. Announces First Quarter 2022 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – May 26, 2022

0

GeneTether Therapeutics Publishes Paper on Novel Recombination Products in the CFTR Gene

San Lorenzo, California – May 11, 2022

0

GeneTether Therapeutics Inc. Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – April 28, 2022

0

GeneTether Therapeutics Completes Initial Public Offering and Announces Listing on the Canadian Securities Exchange

Kelowna, British Columbia – March 29, 2022

0

GeneTether Therapeutics Inc. Files Final Prospectus for Initial Public Offering of Units

Vancouver, British Columbia – March 22, 2022

0

GeneTether Therapeutics Inc. Receives Notice of Allowance from USPTO

Vancouver, British Columbia – February 14, 2022

0

February 2, 2022

GeneTether Therapeutics Inc. Files Amended and Restated Preliminary Prospectus for Initial Public Offering of Units

Vancouver, British Columbia – February 2, 2022

0

November 17, 2021

GeneTether Therapeutics Inc. Files Preliminary Prospectus for Initial Public Offering of Units

Vancouver, British Columbia – November 8, 2021

0